IL2RA and neoplasm: CD25 has been used as a target for the development of antibody-based therapeutics in past studies; although preclinical and clinical studies have demonstrated that these antibodies can actively deplete Tregs, their anti-tumor activity in vivo remained modest [3,17,18,19].